Eisai Announces Plans to Enter Russian Healthcare Market<4523.F><4523.T>
* Reuters is not responsible for the content in this press release.
HATFIELD, England, March 26, 2013 /PRNewswire/ -- Company's plans for global business expansion underscores Eisai's human health care (hhc) mission Eisai EMEA (Europe, Middle East and Africa) announces today the expansion of its operations by establishing a new sales and marketing operation in Russia based in Moscow. Eisai's market entry will be based on launching its in-house developed innovative breast cancer treatment, Halaven(TM) (eribulin). The launch is expected to be during Q2 2013. Following this, Eisai expects to launch its epilepsy portfolio including: Zonegran(R) (Zonisamide), Exalief(R) (eslicarbazepine acetate), and will seek regulatory approval of Fycompa(R) (perampanel) and Inovelon(R) (rufinamide). The Russian healthcare market is large and one of the fastest growing in the world. The pharmaceutical industry has seen significant expansion over the last few years and it holds strong potential for double-digit growth in the next six years. The value of goods and services on the Russian pharmaceutical market is expected to reach USD 22.1 billion by 2016. Analysts estimate that, by 2020, the Russian pharmaceutical market is expected to reach a value of $60 billion, with annual growth rates of at least 15 percent. Commenting on the planned market entry, Gary Hendler, Eisai President & CEO, Russia and EMEA, said: "Eisai's entry into Russia is fully aligned with the company's wider strategy of establishing a solid foundation in the EMEA region. We currently have a number of products in the final stages of approval and hope to launch four to five products within a year of market entry. This will allow Russian patients' to have access to innovative treatments not previously available to them and further supports Eisai's human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide." As part of the company's globalisation strategy set out in its mid-term strategic plan in 2011 "HAYABUSA", Eisai seeks to expand its global presence by 2015 in an effort to achieve its objective of making contributions to more than 500 million patients worldwide. Notes to Editors About Eisai's Commitment to Improving Global Access to Medicines Today, it is estimated that some 2.7 billion* people around the world live on US$ 2 or less per day. Most of these 2.7 billion people do not have access to essential health care and treatment despite the availability of effective medicines. This is an international challenge that needs to be solved through collaborations among governments, international organisations such as the WHO, non-governmental organisations and pharmaceutical companies. In line with its human health care (hhc) mission, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organisations, private entities and non-profit organisations. Specifically, the company has developed and is implementing a five-target approach to improve access to medicines worldwide. The five key components are: product creations, strategic solutions, capacity building, quality innovation, and long-term investment. For further information on Eisai's Access to Medicines initiatives, please visit the Access to Medicines page on the Eisai Global website: http://www.eisai.com/company/atm/index.html * Source: World Bank (2005) About Eisai Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc). Eisai concentrates its R&D activities in three key areas: . Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss . Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc . Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, and inflammatory bowel disease With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. From its Europe based Knowledge Centre in Hatfield, UK, Eisai has recently expanded business operations to include the expanded territory of Europe, the Middle East, Africa and Russia (EMEA). Eisai EMEA undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, Belgium, Luxembourg, the Middle East and Russia. For further information please visit: http://www.eisai.com 1. Russian Pharmaceutical Market Summary http://www.slideshare.net/Shepherd12/russia-pharmaceutical-market-summary (Accessed Jan 2013) 2. Russian Pharmaceutical Market http://russianamericanbusiness.org/web_CURRENT/articles/673/1/Russia%92s-pharmaceutical-market (Accessed Jan 2013) 3. http://www.thepharmaletter.com/file/119809/russian-pharmaceutical-market-continues-to-attract-foreign-investors.html Date of preparation: March 2013 Job Code: Corporate-UK2011 Eisai Europe Limited CONTACT: Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / Cressida Robson, +44-(0)7947-231513 / +44-(0)email@example.com / firstname.lastname@example.org . Tonic Life Communications, Siobhan Reilly / Moira Gitsham, +44-(0)207-798-9999 / +44-(0)7788-191434, email@example.com, firstname.lastname@example.org